In the present study, we performed miRNA-Seq using purified plasma sEVs, which showed immunoreactivity against CD63, Tsg101 and HSP 70, but not calnexin, to investigate the sEVs-derived miRNA expression profiles in patients with NB, including patients with MYCN+ HR, patients with MYCN− HR, MYCN− IR or patients with LR. This evidence concerns the gene MYCN and neuroblastoma.